Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes

被引:14
作者
Akhmedov, Mobil [1 ]
Wais, Verena [1 ]
Sala, Elisa [1 ]
Neagoie, Adela [1 ]
Thanh Mai Nguyen [1 ]
Gantner, Andrea [1 ]
von Harsdorf, Stephanie [1 ]
Kuchenbauer, Florian [1 ]
Schubert, Axel [2 ]
Michel, Detlef [2 ]
Doehner, Hartmut [1 ]
Bunjes, Donald [1 ]
机构
[1] Univ Hosp Ulm, Dept Internal Med 3, Albert Einstein Allee 23, D-89081 Ulm, Germany
[2] Univ Hosp Ulm, Dept Virol, Ulm, Germany
关键词
allogeneic hematopoietic stem cell transplantation; human metapneumovirus; ISI; respiratory syncytial virus; ribavirin; INFLUENZA INFECTIONS; TRACT INFECTIONS; RNA DETECTION; RECIPIENTS; MORTALITY; DISEASE;
D O I
10.1111/tid.13276
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Respiratory viral infections are a major cause of morbidity and mortality among stem cell transplant recipients. While there is a substantial amount of information on prognostic factors and response to ribavirin therapy is available for RSV infections, this information is largely lacking for hMPV. Patients and methods In total, 71 patients were included in this study: 47 patients with RSV and 24 with hMPV. Forty-one patients presented as an upper respiratory tract infection (URTI) and 30 as a primary lower respiratory tract infection (LRTI). Patients were stratified as per ISI criteria into low-, moderate-, and high-risk groups. Twenty-two patients in the URTI cohort received treatment with ribavirin (mainly oral), and 19 patients received no antiviral therapy. The decision for antiviral treatment was at the discretion of the attending physician. All 30 patients with primary LRTI and 10 patients with secondary LRTI were treated with ribavirin, 95% with the intravenous formulation. 45% of these patients received additional treatment with intravenous immunoglobulins. The viral load was assessed indirectly by using the CT value of the RT-PCR. Results In the cohort, as whole 11.5% suffered a virus-associated death, 5% in the URTI group, and 20% in the LRTI group. Sixty-day mortality was significantly higher in the ISI high-risk group (log-rank P = .05). Mortality was independent of the type of virus (P = .817). Respiratory failure with an indication for mechanical ventilation developed in 11.5%, this risk was independent of the type of virus. Progression from URTI to LRTI was observed in 24% of cases with a significantly higher risk (75%) in the ISI high group (log-rank P = .001). In the ISI high-risk group, treatment with ribavirin significantly reduced the risk of progression (log-rank P < .001). Neither the type of virus nor the viral load in the nasopharyngeal swab impacted the risk of progression (P = .529 and P = .141, respectively). The detection of co-pathogens in the BAL fluid was borderline significant for mortality (P = .07). Conclusions We could detect no differences between RSV and hMPV with respect to progression to LRTI, risk of respiratory failure or need for mechanical ventilation and virus-associated death. The ISI index is of predictive value in hMPV patients with a high ISI score and treatment with oral ribavirin has an equivalent protective effect in RSV and hMPV patients. Treatment of LRTI with intravenous ribavirin results in a similar outcome in RSV- and hMPV-infected patients. We could not detect any benefit of adjunctive treatment with immunoglobulins in both primary and secondary LRTI. No role of viral load as an independent prognostic marker could be detected either for progression to LRTI or death.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] How I manage respiratory syncytial virus, human herpesvirus 6 and adenovirus reactivation or infection after allogeneic stem cell transplantation: A report of the SFGM-TC
    Deconinck, E.
    Dalle, J. -H.
    Berceanu, A.
    Chevallier, P.
    Dulery, R.
    Garnier, A.
    Huynh, A.
    Labussiere-Wallet, H.
    Nguyen Quoc, S.
    Dewilde, A.
    Ramon, P.
    Yakoub-Agha, I.
    PATHOLOGIE BIOLOGIE, 2013, 61 (04): : 149 - 151
  • [42] Impact of Body Mass Index on Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Single-Center Retrospective Study
    Braidotti, Stefania
    Curci, Debora
    Zanon, Davide
    Maestro, Alessandra
    Longo, Antonella
    De Vita, Nicole
    Maximova, Natalia
    NUTRIENTS, 2024, 16 (21)
  • [43] Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis
    Mushtaq, Muhammad Umair
    Shahzad, Moazzam
    Shah, Amna Y.
    Chaudhary, Sibgha Gull
    Zafar, Muhammad U.
    Anwar, Iqra
    Neupane, Karun
    Khalid, Ayesha
    Ahmed, Nausheen
    Bansal, Rajat
    Balusu, Ramesh
    Singh, Anurag K.
    Abhyankar, Sunil H.
    Callander, Natalie S.
    Hematti, Peiman
    McGuirk, Joseph P.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [44] Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience
    Nichols, WG
    Gooley, T
    Boeckh, M
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 : 11S - 15S
  • [45] Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus
    Park, Silvia
    Kim, Kihyun
    Kim, Dong Hwan
    Fang, Jun Ho
    Kim, Seok Jin
    Kim, Won Seog
    Jung, Chul Won
    Koh, Kwang Cheol
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (11) : 1630 - 1637
  • [46] Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
    Chien, Sheng-Hsuan
    Yao, Ming
    Li, Chi-Cheng
    Chang, Ping-Ying
    Yu, Ming-Sun
    Huang, Cih-En
    Tan, Tran-Der
    Lin, Cheng-Hsien
    Yeh, Su-Peng
    Li, Sin-Syue
    Wang, Po-Nan
    Liu, Yi-Chang
    Gau, Jyh-Pyng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (12) : 2144 - 2152
  • [47] The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey
    Luis Pinana, Jose
    Perez, Ariadna
    Montoro, Juan
    Hernani, Rafael
    Lorenzo, Ignacio
    Gimenez, Estela
    Dolores Gomez, Maria
    Guerreiro, Manuel
    Maria Gonzalez-Barbera, Eva
    Carretero, Carlos
    Salavert, Miguel
    Balaguer-Rosello, Aitana
    Sanz, Guillermo
    Carlos Hernandez-Boluda, Juan
    Solano, Carlos
    Sanz, Jaime
    Navarro, David
    BONE MARROW TRANSPLANTATION, 2020, 55 (02) : 431 - 440
  • [48] Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients
    Luis Pinana, Jose
    Dolores Gomez, Maria
    Montoro, Juan
    Lorenzo, Ignacio
    Perez, Ariadna
    Gimenez, Estela
    Maria Gonzalez-Barbera, Eva
    Carretero, Carlos
    Guerreiro, Manuel
    Salavert, Miguel
    Sanz, Guillermo
    Carlos Hernandez-Boluda, Juan
    Borras, Rafael
    Sanz, Jaime
    Solano, Carlos
    Navarro, David
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (05)
  • [49] Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens
    Detrait, Marie
    Dubois, Valerie
    Sobh, Mohamad
    Morisset, Stephane
    Tedone, Nathalie
    Labussiere, Helene
    Gillis, Lilia
    Barraco, Fiorenza
    Cannas, Giovanna
    Ducastelle, Sophie
    Fatoum, Jihane
    Thomas, Xavier
    Chelgoum, Youcef
    Nicolini, Franck-Emmanuel
    Michallet, Mauricette
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (10) : 792 - 799
  • [50] Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation
    Marzolini, Maria A., V
    Wilson, Andrew J.
    Sanchez, Emilie
    Carpenter, Ben
    Chakraverty, Ronjon
    Hough, Rachael
    Kottaridis, Panos
    Morris, Emma C.
    Thomson, Kirsty J.
    Peggs, Karl S.
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (08): : 682.e1 - 682.e12